Finerenone meets primary endpoint in Phase III FINEARTS-HF cardiovascular outcomes study in patients with heart failure with mildly reduced or preserved ejection fraction
Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy / Approximately half of all people living with heart failure (HF) have HF with mildly reduced or preserved left ventricular ejection fraction (LVEF), i.e. a LVEF of ≥40%, h…
